What Are the Side Effects of Methazolamide?

Methazolamide, a carbonic anhydrase inhibitor prescribed mainly to lower eye pressure in glaucoma, produces a range of side effects from the merely annoying to the genuinely dangerous. The most common complaints are tingling or numbness in the fingers and toes, fatigue, and stomach upset, which affect roughly a third or more of people who take the drug.¹ But the drug also carries rarer risks that deserve attention, including kidney stones, serious blood disorders, paradoxical eye complications, and severe skin reactions.

The Side Effects You Are Most Likely to Notice

If you start taking methazolamide, there are a handful of effects you should expect as possible rather than surprising. Tingling and numbness, especially in the hands and feet, are among the most frequently reported symptoms. Drowsiness, nausea, stomach discomfort, and loss of appetite round out the everyday complaint list.² Fatigue and a general feeling of being run down also come up consistently in clinical use. One review of carbonic anhydrase inhibitor safety estimated that these common side effects, including tingling, indigestion, tiredness, and fatigue, show up in about 30 to 40 percent of patients.¹

In a small pilot study of sublingual methazolamide, about one in five participants reported mild headaches or fatigue, and no serious adverse events were recorded during the trial period.³ This gives a rough sense of how the drug feels for most people at typical doses: bothersome but manageable. Many of these symptoms lessen over time as the body adjusts, and for some people they fade almost entirely within a few weeks.

Metabolic Acidosis and What It Feels Like

Methazolamide works by blocking an enzyme that helps regulate the balance between acids and bases in your body. A predictable consequence is that your blood becomes slightly more acidic than normal, a state called metabolic acidosis. You might not notice mild acidosis directly, but it underlies many of the common symptoms: the fatigue, the loss of appetite, the general malaise. The tingling in your hands and feet is partly related to how acid-base shifts affect nerve signaling.

The good news is that methazolamide tends to produce milder acidosis than its close relative acetazolamide.⁴ This difference matters in practice because the severity of acidosis tracks closely with how miserable you feel on the drug. One older study found that among patients with chemical evidence of excessive acidosis, roughly ten out of twenty-four reported dramatic relief when given sodium bicarbonate supplements, even though their blood chemistry did not shift much on paper.⁵ That finding suggests the relationship between lab values and how you actually feel is not straightforward, and that bicarbonate supplementation can help some people tolerate the drug better even when the numbers look modest. Expert opinion supports this approach: the review of carbonic anhydrase inhibitor safety noted that bicarbonate supplementation can partially relieve symptoms that do not resolve on their own.¹

Kidney Stones

Kidney stones are an underappreciated risk of carbonic anhydrase inhibitors, methazolamide included. The mechanism connects directly to the metabolic changes the drug causes. When your body becomes more acidic, the chemistry of your urine shifts in ways that promote stone formation: citrate levels drop (citrate normally keeps calcium dissolved), and the urine becomes more hospitable to crystal formation.⁴

A case report documented a patient who developed ureteral colic and a calcium oxalate stone ten months after starting methazolamide. After the stone was removed and the drug was restarted, the patient passed three more calcium phosphate stones within three months, strongly suggesting a causal link between the medication and stone formation.⁶ While that is just one case report, the metabolic pathway connecting carbonic anhydrase inhibitors to stones is well established. If you have a personal or family history of kidney stones, this is worth discussing with your doctor before starting the drug. Staying well hydrated is standard advice for anyone on these medications.

Eye Problems Caused by a Drug Meant to Help Your Eyes

This is one of the more surprising entries on the side-effect list. Methazolamide is prescribed to reduce eye pressure, yet in rare cases it can paradoxically cause a spike in eye pressure and a sudden shift toward nearsightedness. The scenario typically unfolds within the first couple of weeks on the medication: both eyes are affected simultaneously, vision drops, and the patient suddenly becomes significantly more myopic.

In one documented case, a patient developed acute bilateral myopia and secondary angle-closure glaucoma after taking oral methazolamide. Imaging revealed swelling of the ciliary body (the ring of tissue behind the iris) and fluid collecting behind the eye’s drainage structures. The condition resolved after methazolamide was stopped.⁷ Another case showed a patient whose vision dropped to 20/100 in one eye and 20/40 in the other about ten days after starting the drug, with eye pressures climbing well above normal. After discontinuation of methazolamide and treatment with steroids and other medications, pressures normalized within a day and the vision shifts gradually resolved over about a week.⁸

The pattern across these cases is consistent: ciliary body edema, fluid accumulation behind the structures of the eye, shallowing of the front chamber, and choroidal detachment. High-frequency ultrasound in one case confirmed supraciliary effusions and shallow posterior choroidal effusions, all of which resolved nearly completely after the drug was stopped.⁹ The key point for patients is that any sudden change in vision, especially blurriness or pain in both eyes, shortly after starting methazolamide warrants urgent medical attention. The reaction is reversible, but only if the drug is stopped promptly.

Rare but Serious Blood Disorders

The blood-related side effects of methazolamide are rare, but they sit at the severe end of the spectrum. Carbonic anhydrase inhibitors as a class have been linked to disruptions in blood cell production, and methazolamide is no exception. Case reports have documented aplastic anemia (where the bone marrow stops making enough blood cells), agranulocytosis (a dangerous drop in white blood cells), and neutropenia (a less severe but still concerning drop in a specific type of white blood cell).¹⁰

In one early report, two cases of aplastic anemia and one case of agranulocytosis were described in patients taking methazolamide for glaucoma. At least one of the aplastic anemia cases was assessed as almost certainly caused by the drug.¹¹ Aplastic anemia can be life-threatening, and agranulocytosis leaves a person extremely vulnerable to infections. These are not the kind of side effects that resolve on their own or that you can push through.

Because these disorders are so rare, routine blood monitoring is not always performed, which means the first sign of a problem may be symptoms like unexplained bruising, persistent fatigue out of proportion to what the drug normally causes, recurrent infections, or unusual bleeding. Anyone on methazolamide who develops these kinds of symptoms should have blood work done without delay.

Stevens-Johnson Syndrome and Severe Skin Reactions

Stevens-Johnson syndrome and its more severe form, toxic epidermal necrolysis, are among the most feared drug reactions in medicine. They involve widespread skin blistering and detachment that can be fatal. Methazolamide can rarely trigger this reaction.¹² The reaction has been documented across different ethnic backgrounds, though certain genetic markers have been associated with higher susceptibility in some populations, particularly East Asian populations.

The early signs to watch for include a spreading rash, skin pain or tenderness, blistering of the skin or mucous membranes, and flu-like symptoms in the first weeks of starting the drug. If you notice any combination of these, stop the medication and seek emergency care. This is not a wait-and-see situation. The condition is exceedingly rare, but its severity justifies awareness.

How Methazolamide Compares to Acetazolamide

Methazolamide and acetazolamide are closely related drugs that work through the same mechanism. Methazolamide is essentially a modified version of acetazolamide with higher fat solubility, less binding to blood proteins, and less reliance on the kidneys for clearance. The practical result is that methazolamide generally produces fewer side effects than acetazolamide and causes less fatigue.⁴ The metabolic acidosis it produces also tends to be milder.

That said, “fewer” does not mean “none.” Both drugs share the same general side-effect profile: tingling, fatigue, GI upset, metabolic acidosis, risk of kidney stones, and the same rare dangers involving blood disorders and skin reactions. The two drugs also share a class-wide tendency to interact with other medications. The difference is one of degree. If you have struggled with fatigue or GI symptoms on acetazolamide, methazolamide is sometimes tried as a more tolerable alternative, though switching does not guarantee the problems will disappear entirely.

Drug Interactions Worth Knowing About

Carbonic anhydrase inhibitors, methazolamide included, interact with a meaningful number of other drug classes. The metabolic changes these drugs produce, especially the shift toward acidosis and alterations in how the kidneys handle electrolytes, can amplify the effects or toxicity of other medications. A review of drug interactions involving carbonic anhydrase inhibitors emphasized that the risks of toxicity and serious side effects are high when these drugs are combined with certain other drug classes without dose adjustments.¹

Some of the more clinically relevant interactions include:

High-dose aspirin: Both aspirin and methazolamide can contribute to acidosis, and the combination may increase aspirin toxicity while also raising the risk of methazolamide side effects.
Lithium: Methazolamide can alter lithium excretion through its effects on kidney function, potentially pushing lithium levels in either direction.
Other diuretics: Combining methazolamide with potassium-wasting diuretics can accelerate electrolyte imbalances, particularly drops in potassium.
Anticonvulsants: Some seizure medications interact with carbonic anhydrase inhibitors, and the combination can increase the risk of kidney stones beyond what either drug would cause alone.

If you are starting methazolamide and take other medications regularly, your prescriber should review the full list for interactions. This is especially important for people taking multiple drugs for conditions like glaucoma, heart failure, or epilepsy, where carbonic anhydrase inhibitors sometimes fit into a larger medication regimen.

Pregnancy, Breastfeeding, and Methazolamide

Glaucoma management during pregnancy presents a genuine dilemma because the usual drugs all carry some level of risk, and untreated high eye pressure also poses risks. Carbonic anhydrase inhibitors, including methazolamide, have shown evidence of harm to developing animals in laboratory studies, so they are generally avoided during pregnancy whenever alternatives exist.

The picture is different during breastfeeding. Carbonic anhydrase inhibitors are certified by the American Academy of Pediatrics for use during nursing, though low doses are recommended during the breastfeeding period to minimize infant exposure.¹³ This is a situation where the conversation with your ophthalmologist and obstetrician together matters more than any general recommendation, because the decision depends on how severe the glaucoma is and what other treatment options remain available.

Monitoring While on Methazolamide

There is no universal monitoring protocol that every doctor follows for methazolamide, but certain checks make practical sense given the drug’s known risks. Baseline and periodic blood counts can catch early signs of the blood disorders discussed earlier, and periodic electrolyte panels help track acidosis and potassium levels. In the pilot study of sublingual methazolamide, serum electrolyte levels remained stable throughout the study period, while urinary chemistry fluctuated based on when the last dose was taken.³ That pattern suggests serum levels may not always catch what is happening at the kidney level, which is relevant for stone risk.

For the common, quality-of-life side effects like tingling, fatigue, and stomach upset, the evidence supports a trial of sodium bicarbonate supplementation for people who find these symptoms difficult to live with. As noted earlier, some patients report dramatic symptom relief with this approach.⁵ Your doctor can advise on dosing, since too much bicarbonate can create its own problems.

The rare but dangerous side effects, blood dyscrasias, Stevens-Johnson syndrome, paradoxical eye pressure spikes, largely depend on patient awareness rather than scheduled testing. Knowing what early warning signs look like is the most effective form of monitoring for these events. The first few weeks on the drug are the highest-risk window for idiosyncratic reactions, and any new, unexplained symptom during that period deserves a phone call to your prescriber rather than a wait-until-the-next-appointment approach.

Who Is at Higher Risk for Specific Side Effects

While anyone taking methazolamide can experience any of its side effects, certain groups face elevated risk for particular problems. People with a history of kidney stones are at higher risk for stone formation on this drug, for the metabolic reasons already described. Patients with pre-existing liver disease may handle the drug differently because methazolamide is partly metabolized by the liver, which distinguishes it from acetazolamide’s heavier reliance on kidney excretion.

Older adults taking multiple medications are at higher risk for drug interactions and electrolyte disturbances. People with sulfa allergies deserve mention too: methazolamide is a sulfonamide derivative, and while cross-reactivity is debated and not as straightforward as it is sometimes portrayed, a history of severe sulfonamide reactions is generally considered a reason to avoid the drug or use it with extra caution.

Certain genetic backgrounds carry increased susceptibility to Stevens-Johnson syndrome from carbonic anhydrase inhibitors. Research has identified specific genetic markers in East Asian populations that are associated with higher risk. If pharmacogenomic testing is available and you fall into a higher-risk group, it may be worth discussing before starting the medication. For most people in other populations, the risk remains extremely low, but documented cases exist across different ethnic backgrounds as well.¹²

When Methazolamide Is Used Beyond Glaucoma

Though glaucoma is the primary indication, methazolamide has been studied and sometimes prescribed off-label for other conditions, including essential tremor and altitude sickness. The side-effect profile does not change just because the indication is different, but the risk-benefit calculation shifts. For glaucoma, the drug prevents vision loss from a progressive disease, so tolerating moderate side effects may be worthwhile. For altitude sickness prevention, where acetazolamide is the more established drug, methazolamide’s milder side-effect profile and lower rate of fatigue have drawn interest as a potentially better-tolerated alternative.⁴

In a trial evaluating methazolamide for essential tremor, the side effects tracked closely with what is seen in glaucoma use: drowsiness, nausea, stomach discomfort, appetite loss, and tingling.² The drug did not produce any new or unexpected side effects in that context, which is reassuring in the sense that the known risks do not seem to expand when the drug is used for a different purpose. Whether the benefit justifies those risks depends entirely on how debilitating the condition being treated is and what alternatives exist.

1
PubMed. Safety of carbonic anhydrase inhibitors
2
PubMed. Treatment of essential tremor with methazolamide
3
PubMed Central. A Randomized Pilot Study of Four Dosing Schemes of Sublingual Methazolamide in Glaucoma Patients
4
PubMed. Methazolamide in high-altitude illnesses
5
JAMA Ophthalmology. Carbonic Anhydrase Inhibitor Side Effects: Serum Chemical Analysis
6
PubMed. Urinary calculus during methazolamide therapy
7
PubMed. Bilateral transient myopia, angle-closure glaucoma, and choroidal detachment induced by methazolamide
8
PubMed Central. Angiographic features of drug-induced bilateral angle closure and transient myopia with Ciliochoroidal effusion
9
PubMed Central. Acute bilateral angle closure glaucoma induced by methazolamide
10
PubMed. Blood dyscrasias in patients using methazolamide for glaucoma
11
PubMed. Aplastic anemia and agranulocytosis in patients using methazolamide for glaucoma
12
PubMed Central. Methazolamide Associated Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis in a Female of Caucasian Descent
13
PubMed Central. Management of glaucoma in pregnancy: risks or choices, a dilemma?